Penetration of voriconazole, 1%, eyedrops into human aqueous humor: A prospective open-label study

Archives of Ophthalmology

Volumn 126, Issue 3, 2008, Pages 343-346

  Lau, David ^a   Fedinands, Mervyn ^b,e   Leung, Lok ^b   Fullinfaw, Robert ^c   Kong, David ^d   Davies, Geoff ^b   Daniell, Mark ^b  

^a EASTERN HEALTH   (Australia)

^b Royal Victorian Eye and Ear Hospital   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; VORICONAZOLE;

AGED; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TOLERABILITY; DRUG USE; ELECTIVE SURGERY; EYE BURNING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SNEEZING;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; HUMANS; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PYRIMIDINES; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 40849083534     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.71     Document Type: Article

References (22)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79(3):214-221.
2. Sony P, Sharma N, Vajpayee RB, Ray M. Therapeutic keratoplasty for infectious keratitis: a review of the literature. CLAO J. 2002;28(3):111-118.
3. Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea. 2003;22(4):300-333.
4. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol. 1997;81(11):965-971.
5. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol. 1980;90(1):38-47.
6. Bhartiya P, Daniell M, Constantinou M, Islam FM, Taylor HR. Fungal keratitis in Melbourne. Clin Experiment Ophthalmol. 2007;35(2):124-130.
7. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15(4):321-327.
8. Parfitt K. Natacyn (natamycin) product information. Martindale: The Complete Drug Reference. 32nd ed. Chicago, IL: Pharmaceutical Press; 1999:1894.
9. Thomas J. Fungizone (amphotericin) product information. Australian Prescription Products Guide 2007. 36th ed. Hawthorn, Victoria: Australian Pharmaceutical Publishing; 2007:1392-1394.
10. O'Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990;108(7):1006-1008.
11. Thomas J. Australian Prescription Products Guide 2007. Vfend (voriconazole) product information. 36th ed. Hawthorn, Victoria: Australian Pharmaceutical Publishing; 2007:3509-3516.
12. Shah KB, Wu TG, Wilhelmus KR, Jones DB. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea. 2003;22(1):33-36.
13. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-637.
14. Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent). 2003;16(2):241-248.
15. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42-47.
16. Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int J Clin Pract. 2004;58(1):74-80.
17. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39(3):954-958.
18. Sanati H, Belanger RF, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother. 1997;41(11):2492-2496.
19. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(suppl 1):10-16.
20. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis. 2005;40(12):e110-e112. http://www.journals.uchicago.edu/doi/abs/10.1086/430062. Accessed December 13, 2007.
21. Hernández Prats C, Llinares Tello F, Burgos San José A, Selva Otaolaurruchi J, Ordovás Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother. 2004;38(3):414-417.
22. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study [published correction appears in Arch Ophthalmol. 2005;123(1):130]. Arch Ophthalmol. 2004;122(11):1687-1692.